<DOC>
	<DOCNO>NCT01074086</DOCNO>
	<brief_summary>A phase I clinical study evaluation RAD 001 aracytine daunorubicine AML treatment patient old less 65 year relapse</brief_summary>
	<brief_title>Phase I Study RAD 001 Patients With Relapse AML</brief_title>
	<detailed_description>The primary objective study determinate maximal tolerate dose evaluate toxicity RAD 001 patient old less 65 year AML relapse association conventional chemotherapy 5Aracytine Daunorubicine ) dose escalated phase I study .</detailed_description>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>patient 18 65 year old AML relapse 1 year CR inform consent sign age 65 cardiac insufficiency renal insufficiency hepatic disease type AML blastic MCL HIV positive serology malignancy pulmonary infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>RAD 001 relapse AML</keyword>
</DOC>